- Business Wire•3 days ago
CEL-SCI Corporation today announced that it has been notified that it will be granted a new patent on Multikine* , its investigational cancer immunotherapy, from the European Patent Office.
- Business Wire•7 days ago
The following letter is being released by CEL-SCI Corporation to its shareholders:
- Business Wire•19 days ago
CEL-SCI Corporation today announced that Dr. Daniel Zimmerman, its Senior Vice President of Research, Cellular Immunology, is presenting at the 17th Annual World Vaccine Congress held in Washington D.C.
CVM : Summary for Cel-Sci Corporation ($0.001 Pa - Yahoo Finance
CEL-SCI Corporation (CVM)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.11 - 0.16|
|52 Week Range||0.06 - 0.59|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.41|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|